We are live on ! Find out more
DCP

Davern Capital Partners Portfolio holdings

AUM $587M
This Fund
S&P 500
This Quarter Est. Return
+7.47%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$587M
AUM Growth
+$222M
Cap. Flow
+$191M
Cap. Flow %
32.57%
Top 10 Hldgs %
86.76%
Holding
20
New
3
Increased
10
Reduced
2
Closed
5
Avg Time Held
1.3 quarters
Top 10 Avg Time Held
1.3 quarters
Top 20 Avg Time Held
1.3 quarters

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$45.7M
2
BNTX icon
BioNTech
BNTX
+$42.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$34.1M
4
RPRX icon
Royalty Pharma
RPRX
+$33.1M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.6M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$44.8M
2
ARGX icon
argenx
ARGX
+$25.6M
3
LLY icon
Eli Lilly
LLY
+$25.1M
4
ABVX
Abivax
ABVX
+$8.7M
5
VRDN icon
Viridian Therapeutics
VRDN
+$5.92M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BNTX icon
1
BioNTech
BNTX
$24.4B
$70.2M 11.97%
754,550
+449,495
+147% +$42.3M
2025 Q4
2 quarters
ROIV icon
2
Roivant Sciences
ROIV
$25.6B
$68.4M 11.66%
1,932,904
+1,059,506
+121% +$31.3M
2025 Q4
2 quarters
RPRX icon
3
Royalty Pharma
RPRX
$25.3B
$64.8M 11.05%
1,155,809
+635,800
+122% +$33.1M
2025 Q4
2 quarters
IONS icon
4
Ionis Pharmaceuticals
IONS
$7.52B
$63.3M 10.8%
798,709
+411,806
+106% +$31M
2025 Q4
2 quarters
INSM icon
5
Insmed
INSM
$22B
$59.7M 10.18%
559,824
+377,262
+207% +$45.7M
2026 Q1
1 quarter
REGN icon
6
Regeneron Pharmaceuticals
REGN
$76.9B
$57.8M 9.85%
92,640
+47,840
+107% +$32.6M
2025 Q4
2 quarters
LEGN icon
7
Legend Biotech
LEGN
$3.62B
$34.4M 5.87%
1,191,522
-123,226
-9% -$3.32M
2025 Q4
2 quarters
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$31.1B
$34M 5.8%
+113,085
New +$34.1M
2026 Q2
0 quarters
NTRA icon
9
Natera
NTRA
$57.8B
$32.3M 5.51%
118,975
-24,991
-17% -$5.33M
2025 Q4
2 quarters
GPCR icon
10
Structure Therapeutics
GPCR
$1.82B
$23.9M 4.08%
446,059
+319,598
+253% +$14.1M
2026 Q1
1 quarter
MLYS icon
11
Mineralys Therapeutics
MLYS
$2.07B
$23.2M 3.95%
858,753
+411,600
+92% +$11.3M
2025 Q4
2 quarters
VERA icon
12
Vera Therapeutics
VERA
$2.15B
$21.4M 3.65%
+498,832
New +$18.6M
2026 Q2
0 quarters
GENB
13
Generate Biomedicines
GENB
$1.84B
$13.9M 2.37%
824,679
+232,879
+39% +$3.17M
2026 Q1
1 quarter
PRCT icon
14
Procept Biorobotics
PRCT
$1.05B
$10.5M 1.79%
464,920
+203,720
+78% +$5.1M
2026 Q1
1 quarter
AVTX icon
15
Avalo Therapeutics
AVTX
$732M
$8.66M 1.48%
+468,666
New +$7.41M
2026 Q2
0 quarters
ABVX
16
Abivax
ABVX
$7.69B
– –
-78,125
Closed -$8.7M –
ARGX icon
17
argenx
ARGX
$51.9B
– –
-35,045
Closed -$25.6M –
LLY icon
18
Eli Lilly
LLY
$1.05T
– –
-27,279
Closed -$25.1M –
PFE icon
19
Pfizer
PFE
$161B
– –
-1,593,942
Closed -$44.8M –
VRDN icon
20
Viridian Therapeutics
VRDN
$2.11B
– –
-302,457
Closed -$5.92M –

Similar funds

ROC
Running Oak Capital Edina, Minnesota $587M AUM 0.28% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $587M AUM 22.12% 1-Year Est. Return
WPP
Whalerock Point Partners Providence, Rhode Island $587M AUM 29.61% 1-Year Est. Return
HNW
High Note Wealth Deephaven, Minnesota $586M AUM 23.56% 1-Year Est. Return
CFMC
Curbstone Financial Management Corp Manchester, New Hampshire $587M AUM 24.61% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $587M AUM 20.13% 1-Year Est. Return
RFG
REAP Financial Group Austin, Texas $586M AUM 22.63% 1-Year Est. Return
NI
Nuance Investments Kansas City, Missouri $588M AUM 6.93% 1-Year Est. Return

Davern Capital Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Davern Capital Partners held 20 positions worth $587M, up 61% from $365M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Davern Capital Partners deployed $191M of net new capital in Q2 2026, opening 3 new positions and adding to 10 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 113,085 shares worth $34M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Natera, an estimated $5.33M trimmed.

  • Davern Capital Partners's largest Q2 2026 buy was Alnylam Pharmaceuticals: 113,085 shares worth $34M.
  • Davern Capital Partners added most to Insmed in Q2 2026, an estimated $45.7M increase.
  • Davern Capital Partners's biggest Q2 2026 reduction was Natera, cutting an estimated $5.33M.
  • Davern Capital Partners fully exited Pfizer in Q2 2026, selling an estimated $44.8M.
  • Davern Capital Partners's ten largest holdings make up 87% of its $587M portfolio in Q2 2026.
  • Davern Capital Partners opened 3 new positions and closed 5 in Q2 2026.
  • Davern Capital Partners's portfolio value rose 61% quarter-over-quarter to $587M.

Based on Davern Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.